Xiuning Le, M.D.

Medicare patients and services

Medicare patients, 2024

128

Services billed

510

Patients’ average age

74

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 18 companies reported 88 payments worth $96,303 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 13 industry-funded studies in 2025, from 10 companies. The companies reported $2,036,096 in research payments for these studies, mostly to the institutions running them.

• A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04626635
• A Phase I, Multicenter, Open-label, First-in Human, Dose-escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
  AstraZeneca Pharmaceuticals LP
• A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy (ORCHARD)
  AstraZeneca Pharmaceuticals LP
• A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION)
  Merck Healthcare Kgaa
• An Open-Label phase I/II study to evaluate the safety and preliminary efficacy of amivantamab and tepotinib combination in MET-altered non-small cell lung cancer (NSCLC)
  EMD Serono Research & Development Institute, Inc.
• A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
  Beone Medicines USA, Inc. · Terminated · NCT06685718
• A Study of TAS3351 in NSCLC Patients With EGFRmt (TAS3351)
  Taiho Oncology, Inc.
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or …
  AbbVie Inc.
• Study name not reported
  Taiho Oncology, Inc.
• BLU-451-1101
  Blueprint Medicines Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Specialist clinicians in Boston

• Stephen A. Abraham, M.D.
• Stephen I. Alexander, MBBS FRACP MPH
• Robert L. Amrhein, M.D.
• Imelda Auron
• Cynthia A. Austin, ATC
• Angel E. Baricelli, PT, MSPT
• Dorothy M. Brown, MED
• Corrado Cancedda, MD, PHD